iCure is a Korean company applying its advanced transdermal delivery technology to pharmaceuticals and dermo-cosmetics. The company has developed the first-ever transdermal patch for donepezil to reach Phase III clinical trials. Its CEO, Young Kweon Choi, shares his plans for this novel pharmaceutical product, as well as the company’s line of dermo-cosmetics, explains what makes iCure’s technology superior to that of its competitors, and showcases his ambition to become a global leader in the field of transdermal technology.
The goal of iCure is to be the pioneer transdermal patch manufacturer in Asia and ultimately become the global leader in the field
